Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
reference

Gerstberger I, Liebmann M. Regulation of orphan drugs within the EU. European Pharmaceutical Review. 2017;3:14-16

References Cf. Straeter/Burgardt/Bickmann, Arzneimittel für seltene Leiden – Situation in der Europäischen Union, A&R 2014, 195 with further references. Recital 2 of Regulation (EC) No 141/2000. See also Hiltl, Orphan Drugs – Zwischenbilanz und Konfliktfelder, PharmR 2001, 308. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on […]

References

  1. Cf. Straeter/Burgardt/Bickmann, Arzneimittel für seltene Leiden – Situation in der Europäischen Union, A&R 2014, 195 with further references.
  2. Recital 2 of Regulation (EC) No 141/2000. See also Hiltl, Orphan Drugs – Zwischenbilanz und Konfliktfelder, PharmR 2001, 308.
  3. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p.1), last amended by Regulation (EC) No 596/2009 (OJ L 188, 18.07.2009, p. 14).
  4. The amendments that were introduced in 2009 by Regulation (EC) No 596/2009 mainly concerned transferring legislative power to the European Commission.
  5. See first half of the sentence in Art 3 (1) lit a) ODR.
  6. See second half of the sentence in Art 3 (1) lit a) ODR.
  7. Art 3 (1) lit b) ODR.
  8.  See Art 7 (1) ODR.
  9. Art 7 ODR.
  10. Art 6 (1) ODR.
  11. EMA, Explanatory note on general fees payable to the European Medicines Agency, 01 June 2017, p. 42 et seq.
  12. Art 9 ODR.
  13. Art 8 ODR.
  14. According to Art 2 lit c) of Regulation (EC) No. 141/2000, the ‘sponsor’ is defined as “any legal or natural person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product”.
  15. Although the European Commission is instructed to “draw up detailed guidelines on the required format and content of applications for designation” according to Art 5(3) ODR, this has not happened for the past seventeen years.
  16. Cf. Art 5 (1) ODR.
  17. Due to Art 5 (5) ODR.
  18. Art 5 (6) and (7) ODR set out specific procedural rules in case the COMP does not manage to reach a consensus in due time or in case the sponsor does not agree with the opinion of the COMP.
  19. Art 5 (8) ODR.
  20. Art 5 (7) ODR.
  21. Orphan drug status cannot be obtained for medical devices. It is, however, possible to apply for that status in case a product was miscategorised as medical device which in fact has a pharmaceutical effect and must thus be classified as pharmaceutical.
  22. The register can be accessed online via http://ec.europa.eu/health/documents/community-register/html/orphreg.htm.